Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus‒Positive and ‒Negative Relapsed or Refractory Non-Hodgkin Lymphomas

Seok-Jin KIM; Jiyeon HYEON; Inju CHO; Young-Hyeh KO; Won-Seog KIM.
Cancer Research and Treatment ; : 611-622, 2019.
Artículo en Inglés | WPRIM | ID: wpr-763133

Documentos relacionados

  1. Constitutive Interleukin-7 Cytokine Signaling Enhances the Persistence of Epstein-Barr Virus-Specific T-Cells.
  2. Expanded T lymphocytes in the cerebrospinal fluid of multiple sclerosis patients are specific for Epstein-Barr-virus-infected B cells.
  3. Integrated genetic analyses of immunodeficiency-associated Epstein-Barr virus- (EBV) positive primary CNS lymphomas.
  4. Reconstitution of EBV-directed T cell immunity by adoptive transfer of peptide-stimulated T cells in a patient after allogeneic stem cell transplantation for AITL.
  5. EBV and MS: The evidence is growing stronger.
  6. A cost-effective strategy for selection of third-party donors for a virus-specific T-cell bank for an Asian patient population.
  7. Chronic Epstein-Barr virus infection: A potential junction between primary Sjögren's syndrome and lymphoma.
  8. Epstein-Barr Virus-Associated Lymphomatoid Papules: A Sign of Immunosuppression Resembling Lymphomatoid Papulosis.
  9. Investigation of IL-2 and IFN-γ to EBV Peptides in Stimulated Whole Blood among Multiple Sclerosis Patients and Healthy Individuals.
  10. Pathology review identifies frequent misdiagnoses in recurrent classic Hodgkin lymphoma in a nationwide cohort: implications for clinical and epidemiological studies.